Free Trial
→ June 12: Elon Musk’s “Day-One Retirement Plan.” (From Brownstone Research) (Ad)tc pixel
NASDAQ:BLRX

BioLineRx Q1 2026 Earnings Report

BioLineRx logo
$3.19 +0.13 (+4.25%)
As of 10:31 AM Eastern
ProfileEarnings HistoryForecast

BioLineRx EPS Results

Actual EPS
N/A
Consensus EPS
-$1.04
Beat/Miss
N/A
One Year Ago EPS
N/A

BioLineRx Revenue Results

Actual Revenue
N/A
Expected Revenue
$0.34 million
Beat/Miss
N/A
YoY Revenue Growth
N/A

BioLineRx Announcement Details

Quarter
Q1 2026
Date
5/26/2026
Time
Before Market Opens
Conference Call Date
Wednesday, May 27, 2026
Conference Call Time
8:30AM ET

Conference Call Resources

BioLineRx Earnings Headlines

BioLineRx and Hemispherian AS Highlight New Data on GLIX1 at the American Society of Clinical Oncology (ASCO) 2026 Annual Meeting
May 22, 2026  |  prnewswire.comhttps://www.prnewswire.com/news-releases/biolinerx-and-hemispherian-as-highlight-new-data-on-glix1-at-the-american-society-of-clinical-oncology-asco-2026-annual-meeting-302777984.html
BioLineRx to Report First Quarter 2026 Results on May 27, 2026
May 20, 2026  |  prnewswire.comhttps://www.prnewswire.com/news-releases/biolinerx-to-report-first-quarter-2026-results-on-may-27-2026-302777565.html
Porter flew 3,300 miles to investigate this system
Porter Stansberry flew the Porter and Co. team 3,300 miles to Dublin to investigate a 17-year investing experiment called Project Prophet - and documented everything on film. Rooted in the laws of physics, this quantitative approach challenges conventional wealth-building wisdom. With 17 years of verified data behind it, Porter calls it unlike anything he has seen in nearly 30 years in the business.tc pixel
May 26 at 1:00 AM  |  Porter & Company (Ad)
BioLineRx and Hemispherian Announce New GLIX1 Data Demonstrating Potent Anti-Tumor Effect in Glioblastoma (GBM) Across Multiple In-Vivo Studies, Including a Temozolomide (TMZ)-Resistant Model with Patient-Derived Xenografts
May 19, 2026  |  prnewswire.comhttps://www.prnewswire.com/news-releases/biolinerx-and-hemispherian-announce-new-glix1-data-demonstrating-potent-anti-tumor-effect-in-glioblastoma-gbm-across-multiple-in-vivo-studies-including-a-temozolomide-tmz-resistant-model-with-patient-derived-xenografts-302775997.html
BioLineRx (BLRX) Expected to Announce Quarterly Earnings on Tuesday
May 19, 2026  |  americanbankingnews.comhttps://www.americanbankingnews.com/?p=30786535
BioLineRx Ltd.; Hemispherian AS: BioLineRx and Hemispherian Announce First Patient Dosed in Phase 1/2a Study of GLIX1 for the Treatment of Glioblastoma (GBM)
April 28, 2026  |  finanznachrichten.dehttps://www.finanznachrichten.de/nachrichten-2026-04/68325353-biolinerx-ltd-hemispherian-as-biolinerx-and-hemispherian-announce-first-patient-dosed-in-phase-1-2a-study-of-glix1-for-the-treatment-of-glioblastom-008.htm
See More BioLineRx Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like BioLineRx? Sign up for Earnings360's daily newsletter to receive timely earnings updates on BioLineRx and other key companies, straight to your email.

About BioLineRx

BioLineRx (NASDAQ:BLRX) (NASDAQ: BLRX) is a clinical-stage biopharmaceutical company that discovers and develops novel small-molecule therapies to address unmet medical needs. The company focuses on identifying promising drug candidates through licensing and collaboration agreements with academic institutions and biotech innovators, then advancing these candidates through preclinical and clinical development stages. BioLineRx’s pipeline spans oncology, immunology and inflammatory diseases, central nervous system disorders and pain management.

Among its clinical programs, BioLineRx is advancing targeted cancer therapies designed to improve outcomes for patients with difficult-to-treat tumors. In immunology and inflammatory diseases, the company is developing novel agents that modulate key biological pathways to reduce disease activity with minimal side effects. BioLineRx also explores treatments for neuropathic pain and other central nervous system conditions, seeking to offer new therapeutic options where few effective treatments exist.

Headquartered in Modi’in, Israel, BioLineRx maintains strategic partnerships and licensing arrangements across North America, Europe and Asia to support its global development efforts. By leveraging a business model that combines in-licensing, co-development and out-licensing of assets, the company aims to maximize the value of its pipeline while managing development risk. BioLineRx collaborates with contract research organizations and clinical centers worldwide to conduct multi-site trials and accelerate the advancement of its drug candidates.

View BioLineRx Profile
Earnings Tools